Yücel Ustundag1, Hatice Sahin, Sevil İlikhan, Banu Gun Dogan, Firuzan Kokturk, Fatih Kar. 1. Departments of Internal Medicine (YU, HS, SI), Gastroenterology Clinics, Pathology (BGD) and Biostatistics (FIK), Zonguldak Karaelmas University Hospital, Zonguldak, Turkey; and Clinics of General Surgery (FAK), Zonguldak State Hospital, Zonguldak, Turkey.
Abstract
BACKGROUND: Circulating insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-3 levels in the serum of Helicobacter pylori (H pylori)-infected patients were investigated. METHODS: The study subjects consisted of 54 patients with H pylori infection, and the control subjects included 27 patients without H pylori infection. There was no statistical difference in the age and sex distributions between the study and control groups. Pretreatment serum levels of IGF-1 and IGFBP-3 were studied in all the subjects, including the healthy controls. H pylori eradication was achieved with a triple drug regimen for 2 weeks, and 1 month after this treatment, the serum levels of IGF-1 and IGFBP-3 were measured. The post-treatment H pylori status by a second gastroscopy, antral histopathology and urea breath testing was tested. RESULTS: The pretreatment serum levels of IGF-1 and IGFBP-3 of the study and control groups were not found to be different (P > 0.05). H pylori treatment was successful in 42 patients in whom both serum IGF-1 and IGFBP-3 levels decreased with treatment, but the difference was only significant for the serum IGF-1 levels (P: 0.04). There was no change in the serum levels of IGF-1 and IGFBP-3 in the 27 patients with precancereous gastric lesions before and after successful H pylori eradication. CONCLUSIONS: No supporting evidence of a major interaction between H pylori infection itself and H pylori-associated premalignant lesions with circulating IGFBP-3 levels could be shown. Nevertheless, successful eradication of this microorganism led to a statistically significant decrease in serum IGF-1 levels.
BACKGROUND: Circulating insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-3 levels in the serum of Helicobacter pylori (H pylori)-infected patients were investigated. METHODS: The study subjects consisted of 54 patients with H pylori infection, and the control subjects included 27 patients without H pylori infection. There was no statistical difference in the age and sex distributions between the study and control groups. Pretreatment serum levels of IGF-1 and IGFBP-3 were studied in all the subjects, including the healthy controls. H pylori eradication was achieved with a triple drug regimen for 2 weeks, and 1 month after this treatment, the serum levels of IGF-1 and IGFBP-3 were measured. The post-treatment H pylori status by a second gastroscopy, antral histopathology and urea breath testing was tested. RESULTS: The pretreatment serum levels of IGF-1 and IGFBP-3 of the study and control groups were not found to be different (P > 0.05). H pylori treatment was successful in 42 patients in whom both serum IGF-1 and IGFBP-3 levels decreased with treatment, but the difference was only significant for the serum IGF-1 levels (P: 0.04). There was no change in the serum levels of IGF-1 and IGFBP-3 in the 27 patients with precancereous gastric lesions before and after successful H pylori eradication. CONCLUSIONS: No supporting evidence of a major interaction between H pylori infection itself and H pylori-associated premalignant lesions with circulating IGFBP-3 levels could be shown. Nevertheless, successful eradication of this microorganism led to a statistically significant decrease in serum IGF-1 levels.